#rita a rubin

[signourneybooks]

Of Knights and Books and Falling in Love | Book Review

Book: Of Knights and Books and Falling in Love by Rita A. RubinRelease Date: June 29th 2023Tags: New Adult | High Fantasy | Slice of Life Fantasy | Cozy Fantasy | M/M Romance Trigger/Content Warnings: Torture | War victims | Kidnapping Jayce has little memory of life before entering servitude to the Dark Lord, and no hope of ever escaping. Until he meets Alexius, the knight with a heart of gold.…

[heavenlycinema]

In the Heights (2021)

Jon M. Chu (Dir)

“The streets were made of music.”

[nerds-yearbook]

On Febuary 2, 1993, weatherman Phil Connors found himself trapped in a time loop and reliving Groundhog Day over and over. ("Groundhog Day", film)

[historical-hollywood]

Lillian Harvey with Rita and Rubin and a snowman friend in I Am Suzanne! (1933)

[biblionerdreflections]

Book Review - Of Knights and Books and Falling in Love

Hello, everyone! Today I’m reviewing Of Knights and Books and Falling in Love by Rita Rubin. I stumbled upon this one while doom-scrolling one day on Twitter and thought it looked cute. I’ve been in the mood for something cozy and adorable since I haven’t been feeling well recently, and Of Knights and Books and Falling in Love seemed like the perfect book to help me feel better. Jayce has little…

[esonetwork]

Hollywood Sex Goddesses | Tales From Hollywoodland

New Post has been published on https://esonetwork.com/hollywood-sex-goddesses-tales-from-hollywoodland/

Hollywood Sex Goddesses | Tales From Hollywoodland

Dive into the glamorous and seductive world of Hollywood’s most iconic sex goddesses in this captivating episode of the Tales from Hollywoodland Podcast. We explore the lives, careers, and lasting legacies of the silver screen sirens who defined an era with their beauty, charisma, and talent. From Marilyn Monroe to Rita Hayworth, discover how these enchanting women captivated audiences and became timeless symbols of allure. Whether you’re a classic film enthusiast or curious about Hollywood’s golden age, this episode offers a fascinating look at the stars who redefined glamour.

Tales From Hollywoodland on Facebook https://www.facebook.com/talesfromhollywoodland 

Tales From Hollywoodland on Instagram https://www.instagram.com/talesfromhollywoodland/

Tales From Hollywoodland on YouTube https://www.youtube.com/channel/UCdLX2kbwHqdn47FNN6vVN7Q 

We want to hear from you! Feedback is always welcome. Please write to us at  talesfromhollywoodland@gmail.com and why not subscribe and rate the show on Apple Podcast, Spotify, iHeartRadio, Goodpods, PlayerFM, YouTube, Pandora, Amazon Music, Audible, and wherever fine podcasts are found. 

#HollywoodSexGoddesses #IconicActresses #SilverScreenSirens #ClassicFilmStars #HollywoodGlamour #MarilynMonroe #RitaHayworth #GoldenAgeofHollywood #HollywoodBeautyIcons #LegendaryActresses #FilmHistory #HollywoodLegends #VintageHollywood #HollywoodBeautyStandards #HollywoodsGoldenEra #TalesFromHollywoodland #Podcast

[saphirabluish]

Finished these two this week. :)

[the-bi-library]

Happy bi visibility day!!

To celebrate the occasion, here is the part 1 of my bi4bi books posts!

Books listed

They Hate Each Other by Amanda Woody 6 Times We Almost Kissed by Tess Sharpe Stuck with You by 'Nathan Burgoine This Spells Disaster by Tori Anne Martin Check Your Work by Skye Kilaen Troublemaker by Sean Ashcroft Fake It by Lily Seabrooke A Merry Little Meet Cute by Julie Murphy and Sierra Simone Crystals and Contracts by A.A. Fairview Keep Your Witches Close by Colette Rivera Payback’s a Witch by Lana Harper Ride With Me by Jenna Jarvis Melt With You by Jennifer Dugan Trapped in Love by Danica Flynn Butterfly Chances by Margo Phelps Dearly Departed by Heather Novak Sorry, Bro by Taleen VoskuniWhen It All Syncs Up by Maya Ameyaw More To Love by Georgina Kiersten Play by Nikki Markham Let Love Rule by Frances M. Thompson Defying Convention by Cecil Wilde True Love Bites by Joy Demorra Undaunted by Devin Harnois The Girls I've been by Tess Sharpe The Girl in Question by Tess Sharpe Cut & Run by Madeleine Urban Double Exposure by Rien GrayThe Lady Upstairs by Halley Sutton Of Knights and Books and Falling In Love by Rita A. Rubin The Calyx Charm by May Peterson The Sorcerer's Guardian by Antonia Aquilante

Make sure to check the TWs for all books if necessary.

Here is the goodreads list of these books (and many more which I will post soon)

[thistlearts]

Welcome, a new book cover art I made for Rita Rubin as part of her romantasy series about to bi men being hopelessly in love with each other!

[ofmdrecaps]

08/05-06/2024 Daily OFMD Recap

TLDR; David Jenkins; Rhys Darby; Taika Waititi; Vico Ortiz; Samson Kayo; Kristian Nairn; Ruibo Qian; David Fane; Rachel House; Minnie Driver; Dominic Burgess; Aug 7 WBD Q2 Earnings Call: Fuckery; Articles; National Maritime Museum in Cornwall; Fan Spotlight: Cast Cards; Never Left Podcast; Love Notes; Daily Darby/Today's Taika;

Well, best intentions and all that-- another two dayer because that's just how this month has been. Lots and Lots going on with our cast & crew, friends <3

= David Jenkins =

Well David tried to give us all heart attacks yesterday.

And then today he sent some love after Astroglide brought tears to our eyes on twitter.

Source: David Jenkins Twitter

= Rhys Darby =

Lots of Cryptid Factor sightings! Reminder! Cryptid Factor is in London this Friday!

Video of a sighting of Indiana Buttons

Also! Dan and Stede The Nessiehunter gave us some quick live videos of their trip to Lochness!

View this post on Instagram

A post shared by Dan Schreiber (@schreiberland)

View this post on Instagram

A post shared by Dan Schreiber (@schreiberland)

View this post on Instagram

A post shared by Steve Feltham (@steve_the_nessiehunter)

= Taika Waititi =

Another AppleTV spotlight of Time Bandits! Reminder, new episodes out tomorrow, Aug 7!

View this post on Instagram

A post shared by Apple TV (@appletv)

Then Rita pulled Taika into another Tiktok trend.

View this post on Instagram

A post shared by RitaBot | UK Owen (@ritabotowen)

= Samson Kayo =

Samson out with Yvonne Orji <3

Source: Yvonne Orji's Instagram

= Kristian Nairn =

Kristian is reminiscing about Game Of Thrones- his book is coming out on September 24th, 2024-- you can still preorder it online!

Source: Kristian Nairn's Instagram

= Vico Ortiz =

Vico asked what quite a lot of us have wondered about before. IYKYK.

View this post on Instagram

A post shared by Vico Ortiz (@puertoricaninja)

Source: Vico Ortiz Instagram

And some more photos of Vico with their loves.

Source: Vico Ortiz Instagram

= Ruibo Qian =

Ruibo is inviting everyone to join her on Aug 8, at 12am PST for a meditation. You can access it on Ruibo Qian's Youtube!

Source: Ruibo Qian's Instagram

= David Fane =

Some of you may remember that our dear Fang, David Fane, was awarded the Fulbright-Creative New Zealand Pacific Writer's Residency! Now, I'm not 100% sure, but I know that Fulbright partners with the Kennedy Center, and so I'm thinking that's what David's referring to in his most recent instagram story. Good luck David! We are rooting for you!

Source: David Fane's Instagram Stories

= Rachel House =

Rachel's movie, The Mountain (Temaunga) has been officially selected for the Toronto International Film Festival! Congrats Rachel and everyone involved in the film! Learn more on TIFF's website!

Source: Rachel House's Instagram

= Minnie Driver =

Minnie was featured in Rose & Ivy!

Source: Rose and Ivy Journal Instagram

= Dominic Burgess =

Everything about this photo makes me smile.

Source: Dominic's Twitter

== #DontStreamOnMax: Fuckery Reminder ==

Our friends over at @adoptourcrew are calling on everyone to help with the fuckery tomorrow during the Q2 Earnings Call. Remember to flood social media with #DontStreamOnMax and #FireDavidZaslav!

Source: Adopt Our Crew Twitter

== Articles ==

Thank you to Meowzawowza_ on twitter for sharing the contents of this article!

https://if.com.au/allen-marshall-palmer-on-the-benefits-of-shooting-in-new-zealand/

Source: Meowzawowza_ Twitter

= National Maritime Museum Cornwall =

A HUGE thanks to @merryfinches for sharing this absolutely awesome find with us-- and thank you for bringing letting me share it in the recap Kylie! You continue to be one of the sweetest, kindest, most amazing folks on the planet <3 Please visit Kylie's blog here for more info! Here's a quick excerpt! "The exhibit is running until early 2025, so if you’re in Cornwall before it closes then you should go down and stare at a go at floating cardboard cutout of Ed for a bit 🥰💕"

Source: @merryfinches Tumblr

== Fan Spotlight ==

= Cast Cards =

Thank you so much to @melvisik for keeping these up! It's still so amazing to think of just how many people made our show happen! First up is Bradley Rubin, another one of our Production Designers! Second up is Brigid M. who is apparently unspecified (according to https://ofmd-crew.com/)! Mel thinks she may be an action talent!

And last but not least - Stephen Dudro is one of the art directors for the show!

Source: @melvisik's Twitter

== Never Left Podcast ==

Episode 29 is out, and Never Left is continuing with their discussion on flowers! You may remember last weeks episode sparked the butterfly realization to many of the fans! Always great stuff coming out of our friends over at Never Left Podcast! Check them out on your favorite listening platforms here!

Source: Never Left Podcast Instagram

== Love Notes ==

Hey there lovelies! How's your week going? Are you feeling the buzz? There's been lots of news all over the world, some good, some bad, but it feels like a lot of stuff is starting to upturn, even if it's just a little. I've had a few things on my mind the last couple days and I wanted to get them out and send some love. This is a bit of a long one and it's gonna get a bit heavy, so please skip to below the === if you don't feel up for it.

CW: Intrusive Thoughts Sometimes your brain likes to tell you things that you don't really believe (or shouldn't) when things are hard. Sometimes it tells you, you're not good enough, or capable enough, or smart enough, or skilled enough, or you don't deserve good things. Sometimes it tells you things would be better for other people if you weren't around, if you quit your job, or ran away. Sometimes it tells you you don't belong where you are, for any array of reasons. Sometimes it tells you you're unforgivable, or incapable of change.

It's wrong, dearies. It's so very wrong. Your brain sometimes lies to you because it's been trained to do so. By society, by leaders, by people trying to shape you into their worldview. There's nothing wrong with you if it does, it's actually pretty darn normal to feel those things. We deal with so much anxiety in our day to day lives, and our bodies are still stuck on thousands of years of defence mechanisms, and it doesn't know how to cope with the constant micro-stressors we deal with in modern times.

So it learns and adapts to your environment. Your brain is so damn smart-- that it takes what it hears over and over and it turns that inward because it thinks that's what you need. What it doesn't know is that when life is crazy, and the world continues to be this chaotic black hole of unending bad news, it'll adapt and turn things more and more negative. That's why so many people do daily affirmations-- because you can train your brain to do AMAZING things. It takes a long time, and constant reminders, but eventually it gets easier. Toxic positivity isn't helpful, but when you have unending darkness coming in waves around you, sometimes even just a little candle of hope can keep that at bay, and eventually help break up the darkness itself.

============================= So today, I'm gonna push a couple affirmations... and they kinda show up already in my love notes here and there-- but I'd like you take a moment to say them out loud if you can, and take a deep breath in between them --Give yourself a little support for today.

I found some that speak to me here, but you can find them all over the place on the web if they don't speak to you.

----------------

I am still learning so it’s okay to make mistakes.

I am loved and worthy.

I alone hold the truth of who I am.

I belong here, and I deserve to take up space.

I am allowed to feel good.

---------------- You are all of those things Lovelies. You truly are. Do you know why I call you all "Lovelies" so often? Because that's the word that encompasses so much of the good in the world to me-- and that's what you are.

You are lovely, just the way you are.

You are wonderful just the way you are.

You are worthy, and you are loved, and I know sometimes it's so hard to remember that, but keep telling yourself that, and one day it'll come a lot easier. Sending so much love. You deserve so many good things lovelies, please remember that.

== Daily Darby / Tonight's Taika ==

No theme tonight, just them <3 Gif courtesy of our friend @captain-flint!

[covid-safer-hotties]

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits - Published Sept 6, 2024

By: Rita Rubin, MA

As another COVID-19 summer surge hit the US this year, many infected people likely were prescribed the antivirals nirmatrelvir and ritonavir, better known as Paxlovid, for the first time. Or for the fourth time. Or somewhere in between.

Nirmatrelvir-ritonavir, the only approved oral therapy for COVID-19, is recommended for treating mild to moderate SARS-CoV-2 infections among people who are at high risk of progression to severe disease. This includes people aged 50 years or older, especially those 65 years or older, as well as younger individuals who have any of a long list of comorbidities that increase the risk of severe COVID-19.

The clinical trials leading to the US Food and Drug Administration (FDA) authorizing emergency use of nirmatrelvir-ritonavir in December 2021 and approving it in May 2023 were conducted with unvaccinated people who were infected with the now long-gone SARS-CoV-2 Delta variant. This has led to questions about its effectiveness for people who have been vaccinated or have been infected with subvariants of Delta’s successor Omicron, which have been circulating for nearly 3 years.

But recent observational studies suggest nirmatrelvir-ritonavir still protects people at high risk against hospitalization and death from COVID-19. That is if they’re able to get a prescription for it—research has uncovered racial and ethnic disparities in which eligible patients get a prescription for the treatment.

And as the number of people with postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, grows, scientists have been investigating whether nirmatrelvir-ritonavir might be useful in protecting against or treating the condition.

Does It Still Prevent Severe COVID-19?

Because the nirmatrelvir-ritonavir phase 2 and 3 trial involved unvaccinated adults without prior COVID-19 infection when the Delta variant dominated, questions have remained about its relevance today.

Scientists from Pfizer, which markets nirmatrelvir-ritonavir, and coauthors recently published a systematic literature review examining that question. They searched for real-world studies reported from December 2021 through March 2023 and identified 18 that met their final selection criteria.

The evidence showed that nirmatrelvir-ritonavir was effective regardless of age, underlying high-risk conditions, or vaccination status. The treatment significantly reduced the postinfection risk of all-cause and COVID-19–related mortality both within the first 30 days and in the long-term. Treatment started within 5 days of symptom onset, as recommended on the label, was associated with the greatest reduction in postinfection risk.

“We remain very confident in Paxlovid’s clinical effectiveness at preventing severe outcomes, including hospitalization and death, from COVID-19 in patients at high risk of severe disease,” Pfizer spokesperson Kit Longley said in an early August email.

Another recently published study reached a somewhat different conclusion. That study, conducted by University of Manitoba researchers, analyzed results from 4 randomized trials and 16 real-world studies, some of which had not yet been peer-reviewed, with a total of nearly 2 million adults aged 18 years or older.

The evidence suggested nirmatrelvir-ritonavir has a small but significant efficacy in reducing COVID-19 hospitalization and all-cause mortality among people with laboratory-confirmed mild to moderate infections, but the evidence is weak, so more studies are needed, the authors concluded.

At Risk but No Script

COVID-19 laid bare health disparities in the US, and nirmatrelvir-ritonavir has been no exception, according to a study published in August.

Using National COVID Cohort Collaborative (N3C) data, researchers studied individuals 18 years of age or older who were diagnosed with COVID-19 between January 2022 and December 2023; up until the end of that period, the US government covered the cost of nirmatrelvir-ritonavir for everyone who needed it.

About 1.26 million people in the N3C cohort were at high risk of progressing to severe disease, making them eligible for nirmatrelvir-ritonavir treatment. But overall, nearly two-thirds of those who were eligible weren’t prescribed the treatment, the authors observed. After accounting for age, sex, and clinical characteristics, the researchers found that non-Hispanic Black and Latino individuals were nearly a third less likely to have used nirmatrelvir-ritonavir than non-Hispanic White individuals.

Patients may not seek care or may not seek it out early enough for the treatment to be effective, coauthor Hemalkumar Mehta, PhD, a core member of the N3C, speculated in an interview with JAMA Medical News.

Another reason could be that patients don’t have a regular source of primary care whom they could ask for a prescription, noted Mehta, a pharmacist and epidemiologist at the Johns Hopkins Bloomberg School of Public Health. They likely don’t know that the FDA has authorized state-licensed pharmacists to prescribe nirmatrelvir-ritonavir, he said.

Mehta acknowledged that until he conducted his study, even he didn’t realize that pharmacists could prescribe the COVID-19 treatment. Publicizing that fact by simply hanging a sign in pharmacies would help, he pointed out.

However, the FDA created an obstacle to quick prescribing of nirmatrelvir-ritonavir by pharmacists, a 2023 article noted. Prior to prescribing, pharmacists must assess patients’ liver and kidney function through health records from the previous 12 months or consultation with their clinician. Other prescribers can simply ask patients about their liver and kidney function and take their word for it, the authors explained. In addition, there is no standardized pathway for pharmacists to bill payors for assessing patients to see if they’re eligible for nirmatrelvir-ritonavir, which typically takes 15 to 30 minutes, according to the American Pharmacists Association.

When people do get a prescription for nirmatrelvir-ritonavir, most get it filled, a recently published study of Walgreens pharmacies nationwide data found. The retrospective study included people 12 years of age or older for whom a nirmatrelvir-ritonavir prescription was ordered from Walgreens pharmacies between December 2021 and August 2023.

A total of about 2.1 million nirmatrelvir-ritonavir prescriptions were ordered for about 2 million individuals. Among the 95% of people who were prescribed only 1 course of the treatment, 88% filled their prescription. Improving uptake of nirmatrelvir-ritonavir requires increasing patient and prescriber awareness, reducing prescribing disparities, and ensuring treatment initiation within 5 days of symptom onset, the authors concluded.

Treat Acute Infection, Prevent Long COVID?

Taking nirmatrelvir-ritonavir for acute COVID-19 might protect against long COVID, although research into that topic has had mixed results.

For example, 2 recent studies, neither of which had yet been peer-reviewed, reached different conclusions.

A preprint posted in June reported observational study results from the Researching COVID to Enhance Recovery (RECOVER) initiative funded by the US National Institutes of Health (NIH). The study population included nearly 500 000 people who tested positive for SARS-CoV-2 between March 2022 and February 2023. Of those, about 165 000 were treated with nirmatrelvir-ritonavir within 5 days after becoming infected.

Compared with no treatment, nirmatrelvir-ritonavir therapy was associated with a 12% lower risk of developing long COVID within 180 days of infection, or an absolute risk reduction of about 3 cases per 100 people. However, no such risk reduction was seen in people at low risk of severe COVID-19 infection who received nirmatrelvir-ritonavir.

“There are quite a few patients who are not at risk but who received a Paxlovid prescription,” first author Fei Wang, PhD, explained in an interview with JAMA Medical News. “This provides us an opportunity to evaluate a low-risk population that got COVID.”

Another preprint, posted this summer, used N3C electronic health records. It found that nirmatrelvir-ritonavir treatment of acute COVID-19 was not significantly associated with reducing long COVID overall, although it was linked to fewer cognitive and fatigue symptoms.

The mixed findings between the 2 studies aren’t surprising, said Wang, an assistant professor of health care policy and research at Weill Cornell Medicine.

Some information, such as COVID-19 vaccination history and nirmatrelvir-ritonavir use, isn’t always encoded in electronic health records, Wang pointed out. Although he and his colleagues “spend a lot of effort” to make sure they have complete patient information, Wang explained, “there’s no way we can evaluate how complete that is.”

He added that not having a consensus definition of long COVID is another critical issue. The N3C’s definition isn’t the same as RECOVER’s, and the 2 cohorts have different patient populations. “All these can lead to different results,” he said.

For Wang, it makes sense that taking nirmatrelvir-ritonavir, an antiviral, for acute COVID-19 would protect against long COVID. The severity of acute SARS-CoV-2 infections is correlated with the risk of long COVID, he said, and one theory about the cause of PASC is the persistence of SARS-CoV-2 in the body.

However, Yale cardiologist Harlan Krumholz, MD, SM, pointed out that unidentified confounders, not nirmatrelvir-ritonavir itself, might be at play in the relationship between treating acute SARS-CoV-2 infection and long COVID risk. “People who take Paxlovid might be different in many other ways,” he noted.

A Long COVID Treatment?

Many individuals with long COVID didn’t have the opportunity to take nirmatrelvir-ritonavir when they first became ill with acute COVID-19. They might have been infected before the treatment became available, or they weren’t considered to be at high risk for severe disease, so they weren’t eligible for it.

Some case reports have suggested that it might not be too late for people who’ve had long COVID for months to benefit from nirmatrelvir-ritonavir. For example, in early 2023 internist Linda Geng, MD, PhD, codirector of Stanford’s PASC clinic, and coauthors reported the case of a patient who’d had long COVID for 7 months, around which time the symptoms of acute COVID-19 returned. Although rapid antigen test results were negative, the patient had been exposed to multiple people with COVID-19, so a primary care physician prescribed nirmatrelvir-ritonavir. Not only did the acute flu-like symptoms resolve, but so did the long COVID symptoms, which included severe fatigue and cognitive difficulties.

That patient spurred Geng and her colleagues to conduct what they say is the first published randomized trial of nirmatrelvir-ritonavir to treat PASC, which appeared in June in JAMA Internal Medicine. The trial enrolled 155 participants with long COVID, all but 2 of whom had received the primary COVID-19 vaccination series. On average, the time between their initial SARS-CoV-2 infection and randomization into the trial was about a year and a half.

The trial found that the longer 15-day course of nirmatrelvir-ritonavir it used was generally safe. However, the treatment didn’t significantly improve long COVID symptoms compared with the control group.

It’s far from the final answer about nirmatrelvir-ritonavir’s effectiveness against long COVID, though, Geng noted. “This is just the first step in many investigations that need to be done.”

The NIH is funding several clinical trials targeting long COVID under the RECOVER initiative umbrella. One, the Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (RECOVER-VITAL), is testing an even longer course of nirmatrelvir-ritonavir among an estimated 900 participants at centers throughout the US.

And Krumholz and colleagues at Yale University are in the process of analyzing data from their placebo-controlled randomized trial of nirmatrelvir-ritonavir in 100 patients with long COVID. (The trial received funding and design input from Pfizer.)

“We’re not sure it works,” said Krumholz, founder and director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation. “What I think we need are a lot more studies of 100 people or 200 people, trying a lot more things” to treat long COVID.

Participants in the Yale trial were all highly symptomatic and lived throughout the contiguous US. Instead of having them go to participating centers, the trial came to them. “Setting up centers is expensive,” Krumholz explained, noting that the trial’s decentralized design could help cut costs and could work for a variety of conditions and treatments.

Participants were shipped the medication. They gave blood and saliva samples at a local laboratory or at home and answered questions about their symptoms in a digital diary. Yale colleague Akiko Iwasaki, PhD, who studies antiviral immunity and viral disease pathogenesis, is looking at the blood and saliva samples for differences between people who appeared to respond to nirmatrelvir-ritonavir and those who didn’t.

Paxlovid 2.0?

Meanwhile, Pfizer is working to eliminate what one recent publication referred to as nirmatrelvir-ritonavir’s Achilles’ heel: the limited metabolic stability of nirmatrelvir, a protease inhibitor that requires ritonavir to boost it to the target therapeutic range.

The problem is that ritonavir boosts the plasma levels of a long list of other medications beyond the therapeutic range, so nirmatrelvir-ritonavir is contraindicated for people taking them, unless they can temporarily stop or reduce the dose of the concomitant drugs while taking the COVID-19 treatment. Ritonavir is also the source of the metallic taste many individuals who take Paxlovid experience.

Pfizer’s second-generation protease inhibitor for treating COVID-19 is called ibuzatrelvir. Although it’s structurally related to nirmatrelvir, ibuzatrelvir has greater bioavailability when taken orally, so it doesn’t require a ritonavir boost.

Pfizer has completed a phase 2B trial testing the safety and efficacy of a 5-day course of ibuzatrelvir treatment. Participants were nonhospitalized individuals aged 18 to 65 years with confirmed COVID-19 whose symptoms began within 5 days of randomization. Ibuzatrelvir showed robust antiviral activity in the trial, with statistically significant, dose-dependent decreases in viral load at days 3 and 5 compared with placebo, Pfizer researchers reported in April at the European Congress of Clinical Microbiology and Infectious Diseases.

“It is premature to speculate on potential timing of phase 3, but we are considering next steps and plan to share updates as they are available,” Pfizer spokesperson Longley said.

Meanwhile, SARS-CoV-2 continues to evolve along with attitudes toward COVID-19, Krumholz said. Many people “are treating it like a head cold,” he explained. “They’ve obviously made the determination that it’s not dangerous, but it is dangerous.”

Published Online: September 6, 2024. doi:10.1001/jama.2024.16432

[qbdatabase]

I really loved Legends and Lattes by Travis Baldree and Can't Spell Treason without Tea by Rebecca Thorne recently and I'm wondering there's any similar books but with male leads?

Tavern by Deston J. Munden has an asexual male MC who's also an orc working hard to open up his own tavern / restaurant with a found family in a d&d-esque setting

The Glamour Thieves by Don Allman is more urban fantasy, and the shop is robotics / cars, not food, but the male MC is a gay orc

Cursed Cocktails by S. L. Rowland moves away from the orc theme but keeps the cozy fantasy and food / beverage theme with an older gay male MC who retired from adventuring life

Of Knights and Books and Falling in Love by Rita A. Rubin has neither orcs nor food, but it does have books, and it's a very cute cozy fantasy (that does deal with some heavy themes) with an MM couple and a gorgeous cover! (not supposed to judge, but c'mon. look'it that cover)

The Hands of the Emperor by Victoria Goddard is like a combination of courtly intrigue and cozy fantasy between an asexual male court advisor and his king(god), with a beautiful queer platonic relationship that develops between them over a vacation. it's also over 900 pages long

I hope at least one of those has what you're looking for! Thanks for the ask <3

full notes on representation and publishing info at qbdatabase.com

[nerds-yearbook]

On Febuary 1, 1993, weather man Phil Connors, cameraman Larry, and producer Rita Hanson traveled to Punxsutawney, Pennsylvania to see if the groundhog Punxsutawney Phil would see his shadow or not on the following day. ("Groundhog Day", film)

[drrubinspomade]

#rita hayworth

STILL ROCKIN’.

We post glorious pinups like this one all day, every day, all unique! If you dig this pic we’ve found online, u should investigate the creator/subjects of the work and fan them, follow them, hire them.

If you’d like us to remove, or you know who made this so that we can credit, DM. Thanks and greetings from Los Angeles.

YOU ARE THE LIGHT

Dr Rubin’s Pomade

[foxys-fantasy-tales]

Want to find great book recommendations catered to certain interests?

Have I got a place for you. This site is still growing and being worked on, such as adding new ways to search using character types and genres this year! If you're interested, Shepherd.com contacts authors and uses their top five recommendations in their own chosen category related to their own novel and experience. So, if you have an author you like they may have already made a list you can look at to gain more insight! Or you may find their book and name under another author's listed books to see what this new author, as well a their other four recommendations, are all about! This makes a web of interconnected works and personalizes the search process. I really like it, and I was contacted to become a member. My page went live TODAY! 1/30/2023

These are all books I love that I feel have an anime vibe to them. Either because of over the top hijinks and drama that fuel many shonen anime, interpersonal drama and romance that fuels more shojo anime, or just the vibes I got from the work as a whole. Fantasy books and anime can go hand in hand often in my opinion, but these are some of my top recommendations personally. You can click the link above the image to see my reasoning and check out more great lists on the site, such as:

And many, many more lists you can search for currently by topics or lists featuring an author/book title you enjoy. Have fun and find some great reads for your 2023 TBR and beyond!

Also, if you are an author, you can contact the people who run the site and ask to set up your own page for free! Only one novel recommendation list is allowed per author to keep the place from being cluttered when only a couple of people are manually inserting all this information currently.